Novus: Steering Clear of Dilution and Stock Splits

About this update from Novus Acquisition & Development Corp.

Novus Acquisition and Development Corp. (OTC Markets: ( NDEV ) is a leading national supplemental health insurance carrier and pioneer in offering cannabis embedded in health plans for recreational and medicinal users. Presents its perspective on the adverse impacts of dilution and stock splits. Novus, a notable player in the health insurance carrier sector within the cannabis industry, emphasizes the advantages of avoiding dilution and stock splits. With steady EBITDA revenues and Net Asset Value gains, Novus maximizes shareholder value with a robust receivable-based business model that eliminates the need for stock splits, showing our commitment to sustained growth over nearly four years. This strategy lets shareholders benefit from future business expansion while avoiding the downsides of dilution. In contrast, companies resorting to stock splits often signal weakness or adverse challenges. Novus' enduring business model underscores its dedication to navigating the complexities of the cannabis stock landscape. The approval of the Safe Banking Act is expected to trigger a positive shift in the cannabis index. Novus is well-positioned to leverage this growth advantageously. Further Research: Financial Filings:  Click Here Quote: Click Here Website : Click Here Investor's Page : Click Here  About Novus Novus Acquisition & Development Corp. (NDEV) operates through its subsidiary, WCIG Insurance Services, Inc., offering health insurance and related insurance solutions in states with legal medical marijuana programs. With a robust infrastructure covering various insurance lines, including health, life, and fixed annuities, Novus is a leading health insurance carrier, using two key indicators to gauge value and performance. The Benefit Monetization Ratio measures the annual total of monetized policies, offset by the operating cost ratio, a Balance Sheet line item derived from Net Asset Value and calculated to the Price Book Value. Novus' medical cannabis benefits package operates as an outside developer. It does not engage in any activities related to the cultivation, handling, transportation, growth, extraction, dispensing, sale, marketing, vending, delivery, supply, circulation, or trade of cannabis or any substances violating United States law or the Controlled Substances Act. The company adheres strictly to state and federal laws and has no intentions to violate them in the future. It is important to note that statements regarding specific products have not been evaluated by the United States Food and Drug Administration (FDA) and should not be interpreted as intended to diagnose, treat, cure, or prevent disease. The information provided in press releases and product labels is for informational purposes only and should not be considered a substitute for advice from qualified healthcare professionals. Novus respects the individual transactions involving cannabis, which are solely between state-licensed dispensaries and registered patients. However, it's worth noting that state laws may conflict with the federal Controlled Substances Act. The current administration has indicated that federal law enforcement agencies will not prioritize prosecuting those complying with state-designated laws concerning medical marijuana usage and distribution. Nevertheless, changes in government policies and consolidation could impact the provider network, and there is no assurance that future administrations will not alter this stance. While Novus does not engage in the harvest, distribution, or sale of cannabis or cannabis-related products, the company could be affected if there were any shifts in enforcement by federal or state governments concerning existing laws. Such changes could result in significant financial implications for Novus and other industry players. Forward-Looking Statements This release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Dilution, if any, would be for the purposes of management taking stock in lieu of cash salary. Novus disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Additionally, this press release that is not statements of historical fact may be considered to be forward-looking statements. Written words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future.     Investor Contact Information Investor Website 855-228-7355 Email: [email protected]

View stock analysis, news, and events for Novus Acquisition & Development Corp.